ResMed Inc. (RMD) fundamentals from SEC filings — revenue $5.7B, net margin 26.9%, diluted EPS $10.43 in FY2026. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Net income | $779.4M | $897.6M | $1.0B | $1.4B | $1.5B |
| Net margin | 21.8% | 21.2% | 21.8% | 27.2% | 26.9% |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| Free cash flow | $216.3M | $573.6M | $1.3B | $1.7B | $1.6B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home